Compugen (CGEN) Set to Announce Earnings on Tuesday

Compugen (NASDAQ:CGEN) will release its earnings data before the market opens on Tuesday, November 12th. Analysts expect Compugen to post earnings of $0.21 per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Compugen Price Performance

CGEN stock opened at $1.78 on Monday. The stock has a market capitalization of $158.84 million, a P/E ratio of -17.80 and a beta of 2.64. The business has a 50-day moving average of $1.79 and a 200-day moving average of $1.88. Compugen has a fifty-two week low of $0.53 and a fifty-two week high of $3.03.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Compugen from a “hold” rating to a “buy” rating in a research report on Thursday, August 15th.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.